Key terms
About OCGN
Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest OCGN news
May 15 6:36am ET Buy Rating Affirmed for Ocugen on Strong Financials and Advancing Clinical Pipeline by TipRanks May 15 6:32am ET Ocugen completes dosing in second cohort of Phase 1/2 GARDian trial for OCU410ST by TipRanks May 14 8:09am ET Ocugen to begin dosing in Phase 3 liMeliGhT trial in Q2 by TipRanks May 14 8:07am ET Ocugen reports Q1 EPS (5c), consensus (6c) by TipRanks May 14 7:05am ET Options Volatility and Implied Earnings Moves Today, May 14, 2024 by TipRanks May 13 7:00am ET Options Volatility and Implied Earnings Moves This Week, May 13 – May 16, 2024 by TipRanks May 03 8:45am ET Largest borrow rate increases among liquid names by TipRanks Apr 22 7:44am ET Ocugen price target raised to $5 from $4 at Chardan by TipRanks Apr 19 7:14am ET Ocugen announces dosing completion of Cohort 2 in OCU410 Phase 1/2 trial by TipRanks Apr 18 6:03am ET Ocugen files $175M mixed securities shelf by TipRanks Apr 09 8:10am ET Analysts Offer Insights on Healthcare Companies: Staar Surgical (STAA), Ocugen (OCGN) and Moderna (MRNA) by TipRanks Apr 08 6:39am ET Ocugen: FDA clears IND amendment to initiate Phase 3 clinical trial of OCU400 by TipRanks Apr 05 7:04am ET Ocugen says DSMB approves medium dose cohort dosing in OCU410 study by TipRanks Apr 05 3:56am ET Penny Stock Ocugen (NASDAQ:OCGN) Appears Poised For Bigger and Better Things by TipRanks Apr 03 6:25am ET Buy Rating Affirmed for Ocugen on Strong Clinical Progress and Financial Stability by TipRanks Apr 02 8:24am ET Ocugen provides business update by TipRanks Apr 02 7:05am ET Options Volatility and Implied Earnings Moves Today, April 02, 2024 by TipRanks Apr 01 6:11pm ET Ocugen announces positive DSMB review of OCU410ST trial by TipRanks Apr 01 5:22pm ET Ocugen Inc Regains Nasdaq Compliance with Stock Rebound by TipRanks Mar 21 4:33pm ET Ocugen Inc Wins Appeal, Securities Lawsuit Dismissed by TipRanks Mar 21 12:01pm ET Ocugen (NASDAQ:OCGN) Blasts Up 16% as Speculation Mounts by TipRanks Mar 20 5:32pm ET Ocugen Inc Announces Board Departure and Bylaws Amendment by TipRanks Mar 18 9:02am ET Ocugen Inc Bolsters Leadership with New CMO Appointment by TipRanks Mar 18 6:35am ET Ocugen names Huma Qamar, MD, MPH as Chief Medical Officer by TipRanks Mar 13 8:33am ET Ocugen announces dosing completion of Cohort 1 in OCU410 Phase 1/2 trial by TipRanks Feb 28 8:14am ET Ocugen announces availability of Clinical Showcase webcast by TipRanks Feb 23 11:04am ET Biotech Alert: Searches spiking for these stocks today by TipRanks Feb 22 4:09pm ET Ocugen announces dosing completion in Phase 1/2 GARDian clinical trial by TipRanks Feb 22 10:59am ET Biotech Alert: Searches spiking for these stocks today by TipRanks Feb 22 6:20am ET Buy Rating Affirmed for Ocugen on Strong Clinical Progress and Positive Financial Outlook by TipRanks Feb 21 11:32am ET Ocugen Inc to Present at Clinical Showcase in NYC by TipRanks
Today 11:00am ET ONGOING INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm by Accesswire Yesterday 5:41pm ET DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ocugen by Newsfile May 19 11:00am ET IMPORTANT INVESTOR ALERT: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm by Accesswire May 19 7:05am ET INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ocugen by Newsfile May 18 11:00am ET IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm by Accesswire May 18 10:16am ET SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Ocugen, Inc. - OCGN by Newsfile May 17 11:30am ET SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm by Newsfile May 17 11:00am ET DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm by Accesswire May 16 11:50am ET SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm by Newsfile May 16 11:00am ET INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm by Accesswire May 15 6:21pm ET ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - OCGN by Newsfile May 15 10:00am ET INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses In Excess of $250,000 to Contact the Firm by Accesswire May 14 4:44pm ET ROSEN, A LEADING LAW FIRM, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - OCGN by Newsfile May 14 10:00am ET INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm by Accesswire May 13 5:52pm ET DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ocugen by Newsfile May 13 1:00pm ET INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm by Accesswire May 12 3:29pm ET ROSEN, A LONGSTANDING LAW FIRM, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - OCGN by Newsfile May 12 7:48am ET INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ocugen by Newsfile May 10 12:00pm ET INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses In Excess of $500,000 to Contact the Firm by Accesswire May 10 10:17am ET SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Ocugen, Inc. - OCGN by Newsfile May 09 2:32pm ET ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - OCGN by Newsfile May 09 12:00pm ET INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm by Newsfile May 09 8:00am ET INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses In Excess of $250,000 to Contact the Firm by Accesswire May 08 3:30pm ET INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm by Accesswire May 08 1:55pm ET ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - OCGN by Newsfile May 07 2:00pm ET INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm by Accesswire May 06 5:43pm ET DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ocugen by Newsfile May 06 3:20pm ET ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - OCGN by Newsfile May 06 12:00pm ET INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm by Newsfile May 06 8:00am ET INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm by Accesswire May 05 5:35pm ET DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm by Accesswire
OCGN Financials
1-year income & revenue
Key terms
Ad Feedback
OCGN Forecasts
analyst rating
- buy
- hold
- sell
We're sorry, but this
information is
temporarily unavailable.
1-year stock price forecast
OCGN Competitors
$ Market cap P/E ratio $ Price 1d change 52-week range
